Imatinib as a potential antiresorptive therapy for bone disease

Blood

Volumn 107, Issue 11, 2006, Pages 4334-4337

  Dewar, Andrea L ^b   Farrugia, Amanda N ^b   Condina, Mark R ^b   To, L Bik ^b   Hughes, Timothy P ^b   Vernon Roberts, Barrie ^b   Zannettino, Andrew C W ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; IMATINIB; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DISEASE; CELL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; IN VIVO STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33744460465     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3568     Document Type: Article

References (24)

1. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;137:4058-4060.
2. Mundy GR. Bone Remodeling and Its Disorders. London, England: Martin Dunitz Ltd; 1995.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
5. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006-2011.
6. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127-3132.
7. Tanaka H, Matsumura I, Nakajima K, et al. GATA-1 blocks IL-6-induced macrophage differentiation and apoptosis through the sustained expression of cyclin D1 and bcl-2 in a murine myeloid cell line M1. Blood. 2000;95:1264-1273.
8. Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol. 2005;83:48-56.
9. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65:1700-1709.
10. Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98:2808-2816.
11. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188:997-1001.
12. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-3602.
13. Nicholson GC, Malakellis M, Collier FM, et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond). 2000;99:133-140.
14. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999;190:1741-1754.
15. Severson AR. Differentiation of mononuclear cells into multinucleated osteoclast-like cells. Exp Cell Biol. 1983;51:267-274.
16. Marks SC Jr, Lane PW. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J Hered. 1976;67:11-18.
17. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990;87:4828-4832.
18. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993;91:257-263.
19. Amano H, Yamada S, Felix R. Colony-stimulating factor-1 stimulates the fusion process in osteoclasts. J Bone Miner Res. 1998;13:846-853.
20. Begg SK, Radley JM, Pollard JW, et al. Delayed hematopoietic development in osteopetrotic (op/op) mice. J Exp Med. 1993;177:237-242.
21. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999;190:293-298.
22. Niida S, Kondo T, Hiratsuka S, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A. 2005;102:14016-14021.
23. Wolber FM, Leonard E, Michael S, et al. Roles of spleen and liver in development of the murine hematopoietic system. Exp Hematol. 2002;30:1010-1019.
24. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004;104:495-501.